Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Titel:
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Auteur:
Bekaii-Saab, Tanios S Ou, Fang-Shu Ahn, Daniel H Boland, Patrick M Ciombor, Kristen K Heying, Erica N Dockter, Travis J Jacobs, Nisha L Pasche, Boris C Cleary, James M Meyers, Jeffrey P Desnoyers, Rodwige J McCune, Jeannine S Pedersen, Katrina Barzi, Afsaneh Chiorean, E Gabriela Sloan, Jeffrey Lacouture, Mario E Lenz, Heinz-Josef Grothey, Axel